90-Second Read: Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary... The Company is advancing non-clinical development and evaluating the therapeutic combination in validated animal models of Hantavirus and Ebola. Recognizing the critical importance of regional healthcare organizations and rapid deployment, Traws Pharma will build on existing contacts in Nigeria, in particular its relationship with the NAFDAC to develop sustainable, local manufacturing of drug products. Viruses rely entirely on cellular infrastructure to replicate and are dependent on the host cell's internal nucleotide pools.

Redfield, MD Chief Medical Officer of Traws Pharma and former Head of the CDC. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward looking statements. NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. This strategic alignment aims to streamline regulatory pathways and ensure equitable, rapid access to life-saving therapeutics across the African continent.

The investigational combination utilizes a unique "dual-strike" mechanism of action that hijacks host cell pathways to force viral eradication. Importantly, both components of the combination have been safely evaluated in human studies as single agents. The critical studies will be conducted within Biosafety Level 3 (BSL-3) and Biosafety Level 4 (BSL-4) Laboratories. Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027 Tivoxavir marboxil advancing towards a human...